Uma uthatha i-hormone ye-hormone esikhundleni somuthi we-Synthroid, ungase uzwe mayelana nenkantolo yesenzo esenziwe ngokumelene nomkhiqizi wezidakamizwa u-Knoll Pharmaceuticals, kanye nenkampani yomzali BASF, ngasekupheleni kwawo-1990. Lezo zinsolo zixazululwe, kodwa kubalulekile ukwazi ngakho, njengengxenye yomlando walesi sidakamizwa esibizwa nge-levothyroxine.
Umlando othile
Ngawo-1990, i-Synthroid yenziwa yi-Knoll Pharmaceuticals. I-Synthroid ibike ngamaphesenti angama-85 emakethe ye-levothyroxine kusukela ngo-1997. I-Synthroid yayigugu kakhulu ngaphezu kwamncintiselwano, futhi abamele ukuthengisa izidakamizwa kanye nokuthengisa izincwadi bathi imali ephakeme yayifanele njengoba lesi sidakamizwa singcono kunezimbangi zayo. Le nkampani ihlelwe ukufakazela lokhu ngokucwaninga iphinde ithumele isifundo ukukhombisa ukuthi i-Synthroid empeleni yayingcono emtholampilo kunezinye izidakamizwa kanye nezidakamizwa ze-levothyroxine.
Ucwaningo oluqhutshwa nguBetty Dong, MD, lwathola ukuthi i-Synthroid yayilingana, kodwa ayiyona eyinhloko, ekudleni izidakamizwa ze-levothyroxine. Ngaleso sikhathi, uKnoll wadonsela isifundo futhi wavimbela ukushicilelwa kwemiphumela kumaphephandaba wezokwelapha. Ngenxa yokuphikisana kukaKnoll, uDkt. Dong ekugcineni waba nesifundo eshicilelwe.
Ngemva kokushicilelwa kocwaningo lukaDkt. Dong, izigwegwe zesenzo sekilasi zithunyelwe egameni labathengi ababekholelwa ukuthi bakhohliswa ukukhokha ngaphezulu iSythroid.
Isenzo seklasi sasixazululwa ngo-2000, futhi izinkokhelo zokugcina kubathengi zenziwa ngo-2003. (Qaphela: Abathengi abangazange bafake ngaleso sikhathi abakwazi ukuthola imali.)
Isisekelo se-Class Action Lawsuit
Icala laphumela ekuphenyweni, okwaqala ngo-1996, okwakusho ukuthi uKnoll Pharmaceuticals kanye nenkampani yabazali BASF bephule imithetho yokuvikela abathengi ngokuzama ukuvimbela ukushicilelwa kwemiphumela yocwaningo lukaDkt Dong lokucwaninga, olwakubonisa ngokucacile ukuthi igama lomkhiqizo wokukhiqiza nokuncintisana izidakamizwa ze-levothyroxine zazilingana nomkhiqizo we-Synthroid ngokusebenza nokuphepha kweziguli ze-thyroid.
UDkt. Dong utshele iphephandaba i- Journal of the American Medical Association ukuthi lolu cwaningo luye lwacindezelwa iminyaka eyisithupha yinkampani yezidakamizwa. U-Knoll uphinde wacabangela ukuxosha le ncwadi ukuyeka ukushicilelwa kwesifundo.
Leli cala libike ukuthi abasolwa bafihliwe noma banqatshelwe ulwazi mayelana negama lesikhiqizo segama le-bioquivalent kanye nezidakamizwa ze-levothyroxine ezikhiqizayo, bamemezela ngamanga ukuthi kwakungekho okulinganayo kwi- Synthroid , ngakho-ke abathengi abathintekayo ngaphezu kwalokho bekufanele bachithe uma beyazi ukuthi kunezindleko ezibizayo ezinye izindlela.
I-Synthroid Class Action Settlement Settlement
Izindleko zokuqala ngokumelene noNeloll zenani elilinganiselwa ku-$ 8.5 billion. Ngaleso sikhathi ngo-2000, imakethe ye-levothyroxine yayinganiselwa ku-$ 600 million ngonyaka. Kodwa-ke, ukuhlala kwale ndawo kwakwenziwe okuncane kakhulu kunabo ababemangalelwa.
NgoLwesibili, ngo-Agasti 8, 2000, uKnoll Pharmaceutical Company wamemezela ukuthi uJaji Elaine Bucklo weNkantolo yesiFunda yase-US esifundazweni saseNyakatho sase-Illinois wanikeza imvume yokugcina yokuhlelwa kwesinqumo se-Synthroid.
Ukutholwa kwe-akhawunti yokukhipha imali, okungathi ngo-June 30, 2000, kuqukethe cishe amaRandi ayizigidi ezingama-91 kanye nesithakazelo (izimali ezimbalwa zabameli kanye nezindleko) ezikhethiwe ukuba zikhokhwe kubathengi abafake njengengxenye yecala futhi bavuma ukukhulula zonke izimangalo ngokumelene noK Knoll.
Inani elilinganiselwa kumaRandi ayizigidi ezingu-46 kanye nesithakazelo (izimali ezimbalwa zommeli nezindleko) kwakuyokhokhwa amalungu eklasi lokukhokhela abantu abathintekayo.
Ngaleso sikhathi, uKnoll walinganiselwa ukuthi abathengi abangu-778,000 bazothola izinkokhelo ezingaba ngu-R111 000 ngamunye uma beqala ukuthatha i-Synthroid ngaphambi kukaJanuwari 1, 1995, futhi bangaba ngu-R4 74 ngamunye uma beqala ukuthatha i-Synthroid ngemuva kukaJanuwari 1, 1995. Izinkokhelo kwakufanele zithunyelwe ngaphambi ekupheleni kuka-2000 uma kungekho izikhalazo ezifakiwe. Izikhalazo zafakwa, kepha izindawo zokuhlala zaphuza.
Ekugcineni, amasheke ekugcineni athunyelwe kuziguli ekupheleni kuka-2003. Ngaleso sikhathi, iwebhusayithi ezinikezele ekunikezeni ulwazi mayelana nokugwetshwa nokukhokhiswa kwahlehliswa futhi isuswa emgqeni.
Izwi kusuka
Icala ngokumelene nomkhiqizi we-Synthroid we-Knoll Pharmaceuticals kanye nenkampani yomzali BASF yayingakaze ibe nokuphepha noma ukusebenza kwe-Synthroid. Isidakamizwa sasibhekwa ngaso sonke isikhathi siphephile futhi sisebenza kahle. Icala liphikisana nokumaketha ukuthi i-Synthroid-brand levothyroxine yayiphakeme kakhulu emitholampilo kunezinye izinto ze-levothyroxine, nokuthi iqiniso lokuthi inkampani ibike ngaphezulu kwe-Synthroid esekelwe kuleso sizathu samanga.